Omnicell SOAR Analysis

By fiscal 2025, Omnicell had shifted much more of its business toward software and subscriptions, led by Pharmacy-as-a-Service and clinical software modules. That mix creates steadier, recurring revenue and reduces dependence on one-time hospital capital spending, which makes cash flow easier to forecast. A more service-led model also lowers earnings volatility and can support a steadier valuation. For investors, that recurring base is a clear strength.

In fiscal 2025, Omnicell's installed base stayed its biggest strength: over 50,000 active dispensing units and customer retention above 95% create high switching costs and steady demand.

Its shift toward Pharmacy-as-a-Service and other software subscriptions made revenue more recurring and less tied to hospital capex cycles.

Omnicell's safety and compliance tools also matter: its locking and tracking systems cut dispensing errors by nearly 30% and help hospitals manage DEA checks and audits.

Omnicell's international revenue is still only about 10% to 15% of sales, so Europe and Asia remain a clear growth runway. Hospitals there face higher labor costs and nurse shortages; OECD data show health worker gaps are widening in many markets, which strengthens demand for pharmacy and medication automation. Localizing products for European Union and Japanese rules is a key near-term priority, but it can open far larger addressable demand.

Omnicell can grow as care shifts to outpatient and home settings, where U.S. health spending hit $4.9T in 2023 and automation demand is rising. AI inventory tools can become a higher-margin SaaS layer by spotting shortages 2-6 weeks early and lifting recurring revenue.

International sales are still only 10%-15%, so Europe and Asia are a clear runway. Value-based care and traceability in specialty drugs also open new revenue tied to adherence and chain-of-custody.

Omnicell says it aims to help eliminate medication-related errors across the care continuum by 2030, and that goal fits its core identity as a safety-first automation company. Its barcode and biometric interlocks are built to verify the right patient and the right dose every time, which matters in a system where even small errors can trigger serious harm. That mission can also attract clinicians, engineers, and investors who want exposure to measurable patient-safety gains, not just software sales.

Omnicell's 2025 aspiration is to push more of its installed base to cloud-linked automation and reach 60%+ revenue from SaaS and recurring maintenance, shifting the mix toward a stickier, software-like model.

It also wants to scale autonomous pharmacy, with one pharmacist overseeing five or more sites, while targeting fewer medication errors across the care continuum by 2030.

Omnicell's strong operating cash flow over the past two years helped it repay over $200 million of long-term debt by 2025. That deleveraging strengthened the balance sheet and cut annual interest expense, freeing more cash for core operations. With less leverage, Omnicell has more room to pursue AI and robotics M&A in 2025 and beyond.

In fiscal 2025, Omnicell kept recurring revenue near 56% of sales, which made results steadier and less tied to hardware swings. Adjusted EBITDA stayed in the 18% to 21% range, showing the company held margin discipline through cost pressure. Cash flow let Omnicell cut more than $200 million of long-term debt by 2025, which improved flexibility.